Compare · ABBV vs CORT
ABBV vs CORT
Side-by-side comparison of AbbVie Inc. (ABBV) and Corcept Therapeutics Incorporated (CORT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and CORT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $439.62B, about 35.7x CORT ($12.32B).
- CORT has been more active in the news (15 items in the past 4 weeks vs 13 for ABBV).
- ABBV has more recent analyst coverage (25 ratings vs 17 for CORT).
- Company
- AbbVie Inc.
- Corcept Therapeutics Incorporated
- Price
- $248.80-0.01%
- $116.29+1.95%
- Market cap
- $439.62B
- $12.32B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2004
- News (4w)
- 13
- 15
- Recent ratings
- 25
- 17
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Latest ABBV
- AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
- AbbVie Inc. filed SEC Form 8-K: Regulation FD Disclosure
- AbbVie Completes Acquisition of Apogee Therapeutics
- AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
- Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care
- SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings
- AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference
- AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
- AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
- EVP, CHIEF BUS/STRAT OFFICER Donoghoe Nicholas sold $8,177,500 worth of shares (32,710 units at $250.00) and exercised 32,710 shares at a strike of $79.02 (SEC Form 4)
Latest CORT
- Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
- Chief Development Officer Guyer William was granted 328 shares, increasing direct ownership by 8% to 4,313 units (SEC Form 4)
- Officer Maduck Sean covered exercise/tax liability with 117 shares, exercised 25,000 shares at a strike of $8.27, sold $2,860,737 worth of shares (25,000 units at $114.43) as part of a pre-agreed trading plan and was granted 300 shares, increasing direct ownership by 2% to 9,938 units (SEC Form 4) (for withholding tax)
- Chief Financial Officer Mokari Atabak covered exercise/tax liability with 102 shares and was granted 276 shares, increasing direct ownership by 1% to 16,304 units (SEC Form 4) (withholding obligation)
- Chief Business Officer Robb Gary Charles was granted 328 shares and covered exercise/tax liability with 91 shares, increasing direct ownership by 2% to 13,663 units (SEC Form 4) to satisfy withholding obligation
- President, Oncology Vieira Roberto Wandenkolk was granted 276 shares, covered exercise/tax liability with 102 shares, exercised 58,333 shares at a strike of $21.63 and sold $6,460,766 worth of shares (58,333 units at $110.76) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 4,242 units (SEC Form 4) to cover withholding tax
- Officer Lyon Joseph Douglas was granted 260 shares and covered exercise/tax liability with 72 shares, increasing direct ownership by 3% to 5,683 units (SEC Form 4) to cover taxes
- New insider Vieira Roberto Wandenkolk claimed ownership of 4,068 shares (SEC Form 3)
- Director Park Kimberly exercised 30,000 shares at a strike of $13.49, covered exercise/tax liability with 3,315 shares and sold $3,270,169 worth of shares (26,685 units at $122.55) (SEC Form 4)
- Officer Maduck Sean exercised 30,955 shares at a strike of $11.35 and sold $3,887,320 worth of shares (30,955 units at $125.58) as part of a pre-agreed trading plan (SEC Form 4)